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(264±28%), but not in NAc. Extracellular NE (but not 5-HT) in mPFC was also enhanced by the 
combined treatment (472±70%). Repeated (x3) reboxetine+mirtazapine administration produced a 
moderate additional increase in mPFC DA and markedly reduced the immobility time (-51%) in the 
forced-swim test. Neurochemical and behavioral effects of the reboxetine+mirtazapine combination 
persisted in rats pretreated with citalopram (3 mg/kg, s.c.), suggesting its potential usefulness to 
augment SSRI effects.  In situ hybridization c-fos studies were performed to examine the brain areas 
involved in the above antidepressant-like effects, showing changes in c-fos expression in hippocampal 
and cortical areas. BDNF expression was also increased in the hippocampal formation. Overall, these 
results indicate a synergistic effect of the reboxetine+mirtazapine combination to increase DA and NE 
function in mPFC and to evoke robust antidepressant-like responses. 
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Abstract 
Most antidepressant treatments, based on serotonin (5-HT) and/or 
norepinephrine (NE) transporter blockade, show limited efficacy and slow onset 
of action, requiring the use of augmentation strategies. Here we report on a 
novel antidepressant strategy to selectively increase DA function in prefrontal 
cortex (PFC) without the potential tolerance problems associated to DA 
transporter blockade. This approach is based on previous observations 
indicating that extracellular DA in rat medial PFC (mPFC) –but not in nucleus 
accumbens (NAc)- arises from noradrenergic terminals and is sensitive to 
noradrenergic drugs. A low dose of reboxetine (3 mg/kg i.p.; NE reuptake 
inhibitor) non-significantly increased extracellular DA in mPFC. Interestingly, its 
combined administration with 5 mg/kg s.c. mirtazapine (non-selective α2-
adrenoceptor antagonist) increased extracellular DA in mPFC (264±28%), but 
not in NAc. Extracellular NE (but not 5-HT) in mPFC was also enhanced by the 
combined treatment (472±70%). Repeated (x3) reboxetine+mirtazapine 
administration produced a moderate additional increase in mPFC DA and 
markedly reduced the immobility time (-51%) in the forced-swim test. 
Neurochemical and behavioral effects of the reboxetine+mirtazapine 
combination persisted in rats pretreated with citalopram (3 mg/kg, s.c.), 
suggesting its potential usefulness to augment SSRI effects.  In situ 
hybridization c-fos studies were performed to examine the brain areas involved 
in the above antidepressant-like effects, showing changes in c-fos expression in 
hippocampal and cortical areas. BDNF expression was also increased in the 
hippocampal formation. Overall, these results indicate a synergistic effect of the 
*Abstract
reboxetine+mirtazapine combination to increase DA and NE function in mPFC 
and to evoke robust antidepressant-like responses.  
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Abstract 
Most antidepressant treatments, based on serotonin (5-HT) and/or 
norepinephrine (NE) transporter blockade, show limited efficacy and slow onset 
of action, requiring the use of augmentation strategies. Here we report on a 
novel antidepressant strategy to selectively increase DA function in prefrontal 
cortex (PFC) without the potential tolerance problems associated to DA 
transporter blockade. This approach is based on previous observations 
indicating that extracellular DA in rat medial PFC (mPFC) –but not in nucleus 
accumbens (NAc)- arises from noradrenergic terminals and is sensitive to 
noradrenergic drugs. A low dose of reboxetine (3 mg/kg i.p.; NE reuptake 
inhibitor) non-significantly increased extracellular DA in mPFC. Interestingly, its 
combined administration with 5 mg/kg s.c. mirtazapine (non-selective α2-
adrenoceptor antagonist) increased extracellular DA in mPFC (264±28%), but 
not in NAc. Extracellular NE (but not 5-HT) in mPFC was also enhanced by the 
combined treatment (472±70%). Repeated (x3) reboxetine+mirtazapine 
administration produced a moderate additional increase in mPFC DA and 
markedly reduced the immobility time (-51%) in the forced-swim test. 
Neurochemical and behavioral effects of the reboxetine+mirtazapine 
combination persisted in rats pretreated with citalopram (3 mg/kg, s.c.), 
suggesting its potential usefulness to augment SSRI effects.  In situ 
hybridization c-fos studies were performed to examine the brain areas involved 
in the above antidepressant-like effects, showing changes in c-fos expression in 
hippocampal and cortical areas. BDNF expression was also increased in the 
hippocampal formation. Overall, these results indicate a synergistic effect of the 
      Masana et al., 2012 
 3 
reboxetine+mirtazapine combination to increase DA and NE function in mPFC 
and to evoke robust antidepressant-like responses.  
 
Keywords: antidepressant drugs, c-fos, catecholamines, dopamine, 
noradrenaline, prefrontal cortex, forced swim test 
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1. Introduction 
Major depression is a severe psychiatric syndrome with high prevalence and 
socio-economic impact (Andlin-Sobocki et al., 2005; Kessler et al., 2005; Smith, 
2011). Current antidepressant treatments show moderate response and remission 
rates (~50% and ~30%, respectively; Trivedi et al., 2006) making necessary 
augmentation strategies or more aggressive interventions for treatment-resistant 
patients (Carney and Geddes, 2003; Mayberg et al., 2005; Puigdemont et al., 
2011).  
The brainstem serotonergic (5-HT) and noradrenergic (NE) systems are involved 
in the pathophysiology and treatment of major depression (Nestler et al., 2002). 
The limited efficacy and slow onset of action of the selective serotonin reuptake 
inhibitors (SSRI) and the dual serotonin and norepinephrine reuptake inhibitors 
(SNRI) is partly attributable to the activation of presynaptic autoreceptors (5-
HT1A/1B receptors in 5-HT neurons and α2-adrenoceptors in NE neurons) by the 
increased 5-HT/NE produced by reuptake blockade (Artigas et al., 1996; Mateo 
et al., 1998). Repeated antidepressant treatment desensitizes autoreceptors 
and normalizes monoamine release (Bel and Artigas, 1993; Blier and de 
Montigny, 1994; Mateo et al., 2001). Hence, the combined administration of 
monoamine reuptake inhibitors and autoreceptor antagonists synergistically 
increases extracellular 5-HT/NE concentrations, thus mimicking chronic 
antidepressant effects (Artigas et al., 1996; Invernizzi and Garattini, 2004; 
Mateo et al., 1998). This strategy has been applied to augment SSRI effects, 
using the non-selective 5-HT1A/ß-adrenoreceptor blocker pindolol (Artigas et al., 
1994; Perez et al., 1997; see metanalyses in Ballesteros and Callado, 2004; 
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Portella et al., 2011; Whale et al., 2010). However, pindolol is not useful in 
treatment-resistant patients (Pérez et al., 1999) making necessary alternative 
augmentation strategies.  
The dopaminergic system plays a key role in many physiological (e.g., 
cognition, reward) and pathological processes (schizophrenia, drug addition, 
etc.). Thus, abnormal dopamine (DA) function likely underlies certain 
depressive symptoms, such as cognitive dysfunction, lack of motivation and 
anhedonia (Goldman-Rakic, 1999; Goldman-Rakic et al., 2004). Indeed, an 
increased DA function may be beneficial for antidepressant action (D'Aquila et 
al., 2000; Lavergne and Jay, 2010). However, DA transporter (DAT)  blockade 
may not be a convenient strategy due to the profound plastic changes in 
synaptic function (Jones et al., 1998) and the possibility of inducing tolerance or 
abuse (Kuhar et al., 1991; Sora et al., 2001; Woolverton and Johnson, 1992).  
Here we explored the possibility to selectively enhance prefrontal cortex (PFC) 
DA function in order to evoke antidepressant-like effects using a noradrenergic 
drug combination. This strategy is based on the observation that a substantial 
fraction of extracellular DA in PFC derives from noradrenergic axons (Devoto 
and Flore, 2006; Devoto et al., 2001, 2005; Kawahara et al., 2001; Masana et 
al., 2011) being also sensitive to noradrenergic drugs (Masana et al., 2011). 
Thus, we examined the antidepressant properties of the combination of two 
marketed antidepressant drugs, reboxetine (NET inhibitor) and the non-
selective α2-adrenoceptor antagonist mirtazapine. 
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2. Materials and Methods 
2.1. Animals  
Male Wistar rats (250–320 g, Iffa-Credo, Lyon, France) were maintained at 12h 
light/dark cycle, 22±2 ºC room temperature, and food and water available ad 
libitum. Animal care followed European Union regulations (O.J. of E.C. L358/1 
18/12/1986) and was approved by the Institutional Animal Care and Use 
Committee of the School of Medicine, University of Barcelona (Spain).  
 
2.2. Drugs and reagents 
All HPLC reagents used were of analytical grade and obtained from Merck 
(Darmstadt, Germany). DA·hydrochloride, NE·bitartrate and 5-HT·oxalate were 
from Sigma/RBI (Madrid, Spain). Reboxetine·mesylate and mirtazapine were 
from TOCRIS (Avonmouth, UK). Citalopram·hydrobromide was generously 
donated by H. Lundbeck A/S (Copenhagen-Valby, Denmark). Drugs were 
dissolved in saline (pH adjusted to 6-7) in a final volume of 1-2 ml/kg for 
systemic administration. Doses used were: reboxetine 3 mg/kg i.p., mirtazapine 
5 mg/kg s.c. and citalopram 3 mg/kg s.c. (expressed as free bases). In 
experiments involving the repeated administration of reboxetine, mirtazapine 
and citalopram, drugs were dissolved together and given i.p. to avoid an 
excessive number of injections and volume of vehicle.  
 
2.3. In vivo microdialysis experiments 
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Microdialysis experiments were conducted as previously described (Masana et 
al., 2011). Briefly, concentric dialysis probes were implanted under 
pentobarbital anesthesia (60 mg/kg, i.p.) at the following brain coordinates (in 
mm, from bregma and duramater; Paxinos and Watson, 1998): mPFC, AP +3.2, 
L -0.8, DV -6.0, 4 -m membrane length; and NAc, AP +1.6, L -1.1, DV -8.0, 1.5-
mm membrane length. Microdialysis experiments were performed 20-24 h after 
surgery in freely-moving rats, except in experiments involving repeated 
treatment (see section 3.2 in Results). Probes were connected to the perfusion 
pump delivering artificial cerebrospinal fluid at 1.5 µl/min (see Masana et al., 
2011 for details). Experiments detailed in section 3.1 involved dual implants 
(mPFC and NAc), to examine drug effects in both regions of the same animals. 
Monoamine concentrations in dialysate samples were determined by HPLC with 
electrochemical detection (Hewlett Packard 1049, Palo Alto, CA, USA, +0.6 or 
+0.7 V) as described (Bortolozzi and Artigas, 2003; Masana et al., 2011).  
Absolute detection limits were 1–3 fmol monoamine/sample. At the end of 
experiments, animals were killed by a pentobarbital overdose. Brains were 
quickly removed, frozen in dry ice and sectioned (40 µm) with a cryostat 
(HM500-Om Microm, Walldorf, Germany). Coronal brain sections were stained 
with neutral red to verify the correct placement of probes. Only data from rats 
with probes correctly implanted in mPFC and NAc were used. 
 
2.4. Behavioral experiments 
2.4.1. Locomotor activity 
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Motor activity was measured using an Open-Field (OF) apparatus (35 x 35 x 40 
cm) with black plastic walls dimly illuminated (50-60 lx). Locomotor activity was 
recorded during 1 h by a videocamera connected to a computer (Videotrack, 
View Point, Lyon, France) and automatically measured by the video-tracking 
software, as described (Scorza et al., 2010).  
2.4.2. Forced swimming test (FST) 
We used the modified rat FST (Cryan et al., 2002a, 2005). Rats were handled 
daily 1 week before test. In the pre-test session, rats were placed in a clear 
methacrylate cylinder (20 cm wide x 46 cm high) filled with water (24±1ºC; 30 
cm depth) for 15 min. Rats were returned to their home cages after being dried 
off, first with paper towel followed by 15 min into a cage with a heating pad. The 
test was conducted 24 h later in the same cylinder for 5 min and videotaped 
from above. Climbing, swimming and immobility behavior were scored every 5 s 
as previously defined (Detke et al., 1995). Time spent before the first immobility 
score (latency) was also measured (Espejo and Minano, 1999; Pliakas et al., 
2001) and time-course representation was also used for graphic representation 
of individual activity patterns (Chandramohan et al., 2008). Drugs were injected 
23.5, 5 and 1 h before test. 
 
2.5. In situ hybridization experiments 
The effects of reboxetine+mirtazapine administration were examined after acute 
(1 h before sacrifice) and repeated administration (23.5, 5 and 1 h before 
sacrifice, as in FST experiments). Controls received saline with the same time 
schedule. Rats were killed by decapitation with a guillotine. The brains were 
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rapidly removed, frozen on dry ice, and stored at -20°C.  Brain tissue sections, 
14 µm thick, were cut using a microtome-cryostat, thaw-mounted onto APTS (3-
aminopropyltriethoxysilane, Sigma, St Louis, MO, USA)-coated slides and kept 
at -20ºC until use. c-fos oligonucleotide probe was complementary to bases 
131–178 (GenBank ID: NM 022197). BDNF oligonucleotide probe was 
complementary to bases 1188-1237 (GenBank ID: NM 007540). Labeling of the 
probes ([33P]-dATP (>2500 Ci/mmol; DuPont-NEN, Boston, MA), tissue 
sectioning and in situ hybridization procedures were carried out as described 
(Kargieman et al., 2007; Santana et al., 2011). Hybridized sections were 
exposed to Biomax MR film (Kodak, Sigma-Aldrich, Madrid, Spain) for 7 (c-fos) 
or 2 days (BDNF) with intensifying screens. Relative optical densities (R.O.D.) 
were measured with the AIS computerized image analysis system (AIS, 
Imaging Research Inc.), also used to acquire pseudocolor images. Images were 
processed with Photoshop (Adobe Systems, Mountain View) and shown in the 
figures as acquired. Individual values of optical densities were calculated as the 
mean of 2-4 sections per rat (N=4 rats per treatment group).  
 
2.6. Statistical analysis 
Microdialysis results are expressed as fmol/30 µl fraction (uncorrected for 
recovery) or as a percentage of basal values. Area under the curve (AUC) of 
selected time periods was also used. Statistical analysis of neurochemical, 
behavioral and histological data was carried out using Student’s t-test, one- or 
two-way ANOVA for repeated or independent measures, as appropriate, 
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followed by post-hoc Newman-Keuls test. Data are expressed as means±SEM. 
Significance level was set at p<0.05. 
 
3. Results  
3.1. Effects of acute reboxetine+mirtazapine treatment on 
extracellular monoamine concentrations in mPFC and NAc  
Baseline concentrations (fmol/fraction) of monoamines in dialysate  samples 
from mPFC and NAc (dual probe experiments) were respectively: a) DA: 13±2 
(n=34) and 8±1 (n=32); b) NE: 3.5±0.2 (n=9) and 1.9±0.4 (n=10); and c) 5-HT: 
4.0±1.0 (n=11) and 1.9±0.3 (n=10).  
The administration of vehicle, 3 mg/kg i.p. reboxetine, or 5 mg/kg s.c. 
mirtazapine alone did not significantly alter the DA output in mPFC (Fig. 1A,1B). 
However, the combined administration of reboxetine+mirtazapine evoked a 
marked and significant increase of DA in mPFC (264±28 % of baseline; 
F3,22=9.47, p<0.001), significantly different from the rest of groups (post-hoc 
Newman-Keuls test) (Fig. 1A). In contrast, neither drug (alone or in 
combination) significantly altered the DA output in NAc (Fig. 1B).  
SSRI are used as first choice antidepressant treatments. Thus, we examined 
whether citalopram pre-treatment modified the effect of the 
reboxetine+mirtazapine combination, to potentially augment clinical SSRI 
effects. Citalopram pre-treatment (3 mg/kg s.c.) evoked a moderate, non-
significant, increase of DA output in mPFC and did not alter the ability of 
reboxetine+mirtazapine to increase it (Fig. 1C). Two-way ANOVA of mPFC DA 
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revealed a significant effect of reboxetine+mirtazapine treatment (F1,19=25.36, 
p<0.0001) but not citalopram pre-treatment or interaction effect. Neither 
treatment altered the DA output in NAc (Fig. 1D).   
Figs. 1E, 1F and S1 show the change of the extracellular monoamine 
concentrations in mPFC and NAc, respectively, produced by the acute 
reboxetine+mirtazapine combination (AUC of 5 fractions, Fig. S1). The 
combined treatment evoked a very marked increase in DA and NE, but not 
5-HT concentrations in mPFC (Fig. 1E). One-way ANOVA of mPFC data 
revealed a significant effect of the treatment for DA (F1,13=24.72, p<0.001) and 
NE (F1,7=40.93, p<0.001) output, but not for 5-HT output. In NAc, only NE was 
significantly increased by the reboxetine+mirtazapine combination (F1,8=15.85, 
p<0.01) (Fig. 1F).  
 
3.2. Effects of the repeated reboxetine+mirtazapine combination on 
extracellular monoamine concentrations in mPFC 
Given the preferential effects of the reboxetine+mirtazapine combination on 
mPFC DA output, subsequent microdialysis experiments were carried out only 
in this region. Repeated administration of reboxetine+mirtazapine -but not of 
vehicle- significantly increased extracellular DA and NE,  but not 5-HT, in mPFC 
(Fig. 2). Reboxetine+mirtazapine increased extracellular DA from 9±2 to 23±5, 
36±3 and 35±2 fmol/fraction (baseline, first, second and third administrations, 
respectively) (Fig. 2A). Repeated vehicle administration did not modify DA 
output in mPFC (10±1, 12±2, 12±2 and 18±4 fmol/fraction baseline, first, 
second and third administrations, respectively) (Fig. 2A). Two-way ANOVA 
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showed a significant effect of the treatment (F1,6=17.24, p<0.01), number of 
injection (F3,18=24.76, p<0.0001) and interaction between both factors 
(F3,18=12.46, p<0.001).   
The reboxetine+mirtazapine combination increased NE output from 5±2 
fmol/fraction to 28±3, 33±3 and 30±6 fmol/fraction (baseline, first, second and 
third administrations, respectively) (Fig. 2B). Repeated vehicle administration 
did not modify NE output in mPFC (4±1, 4±1, 3±1 and 4±1 fmol/fraction; 
baseline, first, second and third administrations, respectively). Two-way ANOVA 
showed a significant effect of the treatment (F1,6=34.34, p<0.01), number of 
injections (F3,18=21.55, p<0.0001) and interaction between both factors 
(F3,18=22.91, p<0.0001). 
5-HT output in mPFC (Fig. 2C) was unaltered by repeated 
reboxetine+mirtazapine administration (2.2±0.2, 2.1±0.2, 3.7±1.7 and 2.3±0.5 
fmol/fraction; baseline, first, second and third administrations, respectively) or 
repeated vehicle administration (1.7±0.2, 1.6±0.2, 1.8±0.3 and 1.9±0.5 
fmol/fraction; as above). 
 
3.3. Antidepresant-like effect of reboxetine+mirtazapine in the forced 
swimming test (FST)  
Fig. 3a shows the effects of the various treatments used on FST variables (total 
immobility score, swimming and climbing behaviors). At the dose used, 
reboxetine and mirtazapine alone did not significantly reduce FST variables. 
However, its combined administration evoked a synergistic 51% reduction in 
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immobility (F3,30=3.31, p<0.05) with a non-significant increase in climbing or 
swimming scores. 
The administration of 3 mg/kg i.p. citalopram did not reduce immobility. 
However, the subsequent treatment of the reboxetine+mirtazapine combination 
induced a marked decrease in immobility (46% of citalopram-treated rats, 
p<0.01; Student’s t-test), and an increase in climbing (125% of citalopram-
treated rats, p<0.05; Student’s t-test)  
We further examined the latency to immobility (Fig. 3B). This variable has been 
used as a measure of the time spent by rodents fighting against an aversive 
situation (Castagne et al., 2009; Espejo and Minano, 1999; Pliakas et al., 2001). 
The reboxetine+mirtazapine combination –but not either drug alone- induced a 
very marked increase of this variable (from 81 to 153 seconds; F3,30=7.62, 
p<0.001). As observed with the reduced immobility time, the increased latency 
persisted in citalopram-pretreated rats (from 53 to 134 seconds; p<0.05, 
Student’s t-test) 
Fig. 3c shows the individual behavior of all rats used in FST experiments 
(Chandramohan et al., 2008). The behavior of each rat is depicted by a 
horizontal line during the 5-min observation period. Each 5-s color-coded pixel 
represents the predominant behavior of the rat (black = climbing; grey = 
swimming; white = immobility). Rats treated with reboxetine+mirtazapine, alone 
or in combination with citalopram, exhibited the most active behaviors (greater 
density of black/grey pixels).  
The effects of the reboxetine+mirtazapine combination in the FST are not due 
to an increase in motor activity, since the combination treatment did not alter the 
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distance moved in the open-field nor the number of rearings, yet it moderately 
decreased gromming behavior (data not shown).  
  
3.4. Effects of acute and repeated reboxetine + mirtazepine treatment 
on c-fos mRNA expression  
c-fos  expression was used to assess the brain areas involved in the 
antidepressant-like effects of the reboxetine+mirtazapine combination. Relative 
optical densities (R.O.D.) were measured in coronal brain sections (see section 
2.5 in Methods) and results are expressed as percentages of vehicle-treated 
rats. Fig. 4A shows representative sections at various AP levels of vehicle- and 
reboxetine+mirtazapine-treated rats. Fig. 4B shows the effect of the single and 
repeated administration of reboxetine+mirtazapine on c-fos expression in 
representative brain areas. Single administration significantly increased c-fos 
expression in the entorhinal cortex and reduced it in mPFC and hypothalamus 
as shown by two-way ANOVA of R.O.D. values: effect of region (repeated 
measure; F8,48=11.73, p<0.001) and region by treatment interaction 
(F8,48=11.73, p<0.001; Fig. 4B, upper panel).  Repeated reboxetine+mirtazapine 
administration significantly elevated c-fos expression in the entorhinal cortex 
and the dentate gyrus, and normalized c-fos expression in the mPFC and 
hypothalamus: effect of treatment (F1,5=7.34, p<0.05), region (repeated 
measure, F8,40=2.94, p<0.05) and region by treatment interaction (F8,40=2.94, 
p<0.05)   (Fig. 4B, lower panel). 
3.4.1. Effects on BDNF and c-fos expression in the hippocampal formation 
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We carried out an additional study to examine the effect of the repeated 
reboxetine+mirtazapine combination on BDNF and c-fos expression in various 
hippocampal subfields at a more rostral AP coordinate (-2.8 mm; Fig. 5A). Two-
way ANOVA indicated a significant increase of BDNF mRNA in CA1 and CA2 
areas: region effect (F3,18=6.48, p<0.01) and region by treatment interaction 
(F3,18=6.48, p<0.01).  c-fos expression was also increased in the dentate gyrus 
(two-way ANOVA, region effect (F3,18=7.41, p<0.01) and region by treatment 
interaction effect  (F3,18=4.96, p<0.05)).  
 
4. Discussion 
We recently reported that the combination of the NET inhibitor reboxetine and 
the selective α2-adrenoceptor antagonist RX821002 (not available for human 
use) evoked a marked and selective increase of extracellular DA in PFC 
(Masana et al., 2011). Here we confirm and extend these previous observations 
using the non-selective α2-adrenoceptor antagonist mirtazapine, a marketed 
antidepressant drug. The neurochemical, behavioral and gene expression 
effects evoked by this antidepressant drug combination suggest its usefulness 
to treat PFC- and catecholamine-dependent depressive symptoms (e.g., 
cognitive impairment, lack of motivation, psychomotor retardation, etc.) 
Likewise, an enhanced DA function in PFC may be a useful way to treat 
cognitive deficits and negative symptoms in schizophrenic patients, which lack 
specific pharmacological treatments. 
The present neurochemical data (Figs. 1, 2) agree with previous observations 
indicating that noradrenergic drugs can enhance DA transmission in PFC 
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(Carboni et al., 1990; Devoto et al. 2001, 2005; Devoto and Flore 2006; Masana 
et al., 2011; Mazei et al., 2002; Pozzi et al., 1994). In particular, a recent report 
from our group (Masana et al., 2011) showed that DA output in mPFC(but not in 
NAc), was enhanced by reboxetine (selective NE reuptake inhibitor) and 
nomifensine (dual NE/DA reuptake inhibitor), but not by the selective DA 
reuptake inhibitor GBR12909. Moreover, electric stimulation of the locus 
coeruleus enhanced extracellular DA in mPFC and not in NAc. In agreement 
with a major contribution of noradrenergic axons, extracellular DA in mPFC was 
sensitive to α2-adrenoceptor blockade with RX821002, as observed with the 
PFC NE output (Invernizzi and Garattini, 2004; Mateo et al., 1998; Ortega et al., 
2010; Sacchetti et al., 1999). 
After more than two decades of antidepressant drug development based on 
single or dual targets (e.g., SSRI, SNRI), current trends are focused on multi-
target drugs that i) reduce the efficacy of negative feed-back mechanisms 
operating in monoaminergic neurons, and/or ii) increase the function of all 
monoamine systems (e.g., triple reuptake inhibitors). The first approach is 
based on drug combinations targeting several monoaminergic elements that 
overcome SSRI/SNRI limitations (Artigas et al., 1994, 1996; Blier et al., 2010; 
Carpenter et al., 2002; Chen and Skolnick, 2007; Lopez-Munoz et al., 2006; 
Millan, 2009; Papakostas et al., 2006; Trivedi et al., 2006). On the other hand, 
triple reuptake inhibitors increase extracellular concentrations of 5-HT, NE and 
DA, without the severe side effects of MAO inhibitors. These drugs appear to be 
superior in terms of shorter onset of action than conventional antidepressants 
(Chen and Skolnick, 2007; Millan, 2009). However, the blockade of DA 
transporter may involve tolerance or abuse problems (Haddad, 1999).  
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The present study shows the feasibility of selectively increasing cortical (but not 
mesolimbic) catecholaminergic transmission using marketed drugs. Hence, as 
proposed (Masana et al., 2011), NET blockade would increase the extracellular 
NE concentration, resulting in an enhanced activation of terminal (and possibly 
somatodendritic) α2-adrenoceptors, which would attenuate noradrenergic cell 
firing and NE release. Blockade of α2-adrenoceptors would counteract 
autoreceptor-mediated negative feedback, leading an enhanced NE release.  
DA, stored in the same synaptic vesicles as NE, would therefore be subjected 
to the same processes (Masana et al., 2011). 
In contrast to the marked increase of extracellular DA and NE concentrations in 
the mPFC, the reboxetine+mirtazapine combination did not alter extracellular 
DA and only increased moderately extracellular NE in NAc. This effect may be 
due to the different regional NE innervation in rat brain and to the greater 
contribution of DA axons to extracellular DA in NAc. Hence, the locus coeruleus 
is the main NE source for noradrenergic PFC innervation whereas it has a low 
contribution in NAc, where the nucleus of the solitary tract is the main NE 
source (Berridge et al., 1997; Delfs et al., 1998; Foote et al., 1983; Seguela et 
al., 1990). On the other hand, the large density of DA fibers in NAc –compared 
to PFC- minimizes the noradrenergic contribution to extracellular DA in the NAc. 
The marked increase in extracellular DA and NE in PFC produced by 
reboxetine+mirtazapine was accompanied by a substantial reduction of the 
immobility score in the FST. This effect most likely resulted from the synergistic 
interaction between both drugs. Although various neurotransmitters and 
receptors have been implicated in antidepressant response in the FST (Cryan 
et al., 2002b; Page et al., 1999, 2003; Reneric and Lucki, 1998), the parallel 
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changes in PFC DA/NE release and FST variables induced by the 
reboxetine+mirtazapine combination support the view that an increased cortical 
DA –and likely NE- function underlies the behavioral action of this drug 
combination. The neurochemical and behavioral effects of 
reboxetine+mirtazapine were unaffected by citalopram pretreatment, suggesting 
that this drug combination can be efficiently used as an augmentation strategy 
in patients treated with –but not responding to- SSRI. 
Interestingly, the marked reduction of immobility produced by 
reboxetine+mirtazapine and its combination with citalopram was obtained with 
doses of both drugs that are ineffective when given alone, in agreement with 
data in the literature (Connor et al., 1999; Mague et al., 2003; Reneric et al., 
2002). This further supports the above interpretation of the mechanism of 
action, likely resulting from a synergistic interaction between NET blockade and 
α2-adrenoceptor blockade. Furthermore, the present results agree with previous 
studies showing that the combination of desipramine (NET inhibitor) + idazoxan 
(α2-adrenenoceptor antagonist) + fluoxetine (SERT inhibitor) produced a greater 
reduction of the immobility time, as well an increase of swimming and climbing 
behaviors (Reneric et al., 2001).  
C-fos expression is widely used to label activated cells after physiological or 
pharmacological stimuli (Sagar et al., 1988). We used the expression of this 
early gene to examine the rat brain areas involved in the effects of the 
reboxetine+mirtazapine combination. Moderate changes in c-fos mRNA were 
observed. Notably, an increase in the entorhinal cortex which was accompanied 
by a simultaneous decrease in mPFC and hypothalamus after single 
reboxetine+mirtazepine administration and by an increase in the dentate gyrus 
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after repeated administration. However, c-fos expression remained unaltered in 
other brain areas such as nucleus accumbens or septum, which are affected by 
other antidepressant drugs (fluoxetine, imipramine, reboxetine) (Beck 1995; 
Torres et al., 1998; Svenningsson et al., 2007; Slattery et al., 2005; Miyata et 
al., 2005).  The unchanged c-fos expression in the present study cannot be 
attributed to methodological reasons, since similar in situ hybridization 
procedures were able to detect c-fos changes in various brain regions after the 
administration of drugs that increase neuronal discharge (Kargieman et al., 
2007; Lladó-Pelfort et al., 2011; Santana et al., 2011).  More likely, regional 
differences in the effect of antidepressant drugs can be due to the different 
mechanism of action (i.e., SSRI vs. noradrenergic antidepressants) and, more 
specifically to the drug combination used herein, which simultaneously elevated 
PFC DA and NE function. Indeed, Slattery et al., (2005) reported an increased 
c-fos expression in the shell of NAc after single mirtazapine administration (2 
mg/kg). Likewise, Miyata et al., (2005) reported an increase in c-fos 
immunoreactivity in the same region after single reboxetine administration (5 
and 10 mg/kg). However, this is the first study examining the effects of the 
combination of both drugs. 
The unaltered c-fos expression in mPFC after repeated reboxetine+mirtazapine 
administration suggests that the increase in mPFC catecholamine function is 
not sufficient to trigger the expression of this immediate early gene, which 
requires marked changes of neuronal discharge (Sagar et al., 1988). In 
agreement, fluoxetine -which moderately increased the activity of PFC neurons 
(max. increase of 53%; Ceci et al., 1993)- did not alter c-fos expression in this 
area (Salchner and Singewald, 2002). 
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Interestingly, single and repeated administration of reboxetine+mirtazapine 
evoked a similar increase of c-fos expression in the entorhinal cortex, an effect 
possibly related to the antidepressant-like effects in the FST. Indeed, the 
entorhinal cortex is the main input and output structure for the hippocampal 
formation (van Groen et al., 2003), where antidepressant drugs increase the 
expression of neuroplasticity-associated genes, such as BDNF (Nibuya et al., 
1995). Hence, the activation of the entorhinal cortex may be a previous step for 
the well-known antidepressant-induced change in hippocampal activity, as 
recently reported using high frequency stimulation of the entorhinal cortex 
(Stone et al., 2011). Indeed, here we found that the repeated (x3) administration 
of low doses of the reboxetine+mirtazapine combination evoked changes in 
hippocampal c-fos and BDNF, as observed after chronic SSRI treatments 
(Duman, 2004) or with a much higher reboxetine dose (20 mg/kg·day; Russo-
Neustadt et al., 2004). Our observations also agree with a recent report 
indicating that α2-adrenoceptor blockade with yohimbine enhanced the effects 
of imipramine on neuroplasticitry genes and behavioral measures of 
antidepressant effect (Yanpallewar et al., 2010).  
In summary, we show that the combination of drugs targeting NET (e.g., 
reboxetine) and α2-adrenoceptors (e.g., mirtazapine) can be a useful 
antidepressant strategy to augment the effects of SSRI, by selectively 
increasing catecholaminergic neurotransmission in PFC. In particular, the 
increased DA function in PFC evoked by this drug combination may contribute 
to improve cognitive dysfunction and lack of motivation in depressed patients. 
Likewise, this may be also useful to treat cognitive deficits and negative 
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symptoms in schizophrenia patients, associated to a hypoactive dopaminergic 
function in PFC. 
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Legends to Figures 
 
Fig. 1. Effect of single reboxetine, mirtazapine and its combination treatment on 
extracellular monoamine concentration in mPFC (left) and NAc (right).  Bars 
show the average effect of vehicle, reboxetine (Reb), mirtazapine (Mirt) and 
Reb+Mirt in (a) mPFC and (b) NAc. Citalopram (Cit) pretreatment did not modify 
the effects of Reb+Mirt on DA concentration in (c) mPFC nor (d) NAc.  The 
Reb+Mirt combination increased extracellular NE concentration -but not that of 
5-HT- in (e) mPFC and (f) NAc. Data are AUC of five 20-min fractions, 
expressed as percentage of baseline (see collection period in Fig. S1). N=4-8 
rats/group; *p<0.05 and **p<0.01 vs vehicle; ζp<0.05 vs reboxetine and 
mirtazapine; ap<0.05 treatment effect; n.s. non-significant. 
 
Fig. 2. Effect of repeated reboxetine+mirtazapine combination treatment on 
extracellular monoamine concentration in mPFC (a) DA, (b) NE and (c) 5-HT. 
Bars show absolute monoamine values after administering the drug 
combination using the FST protocol. Data are AUC of four (baseline) and six 
(1st, 2nd and 3rd injection) 20-min fractions, expressed as fmol/fraction. N=4 
rats/group. *p<0.05 and **p<0.01 vs vehicle; ≠p<0.05; ≠p<0.01 vs the respective 
baseline and ζζp<0.01 vs first injection for respective treatment. 
 
Fig. 3. Drug effects on forced-swim test (FST) variables. Bar graphs showing 
the effect of treatments on (a) immobility, swimming and climbing scores and (b) 
latency to the first immobility count in the FST. (c) Individual raw data from FST 
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experiments. Each horizontal line corresponds to the behavior of a single rat. 
Time (abscissa) corresponds to the 5 min of FST. Each color-coded pixel 
represents 5 s of behavioral activity (black- climbing, grey-swimming, white-
immobility). Vertical black line indicates mean latency to first immobility. N=7-10 
rats/group; *p<0.05 and **p<0.01 vs vehicle; ≠p<0.05 and ≠≠p<0.01 vs 
citalopram; ζζζp<0.001 vs Reb and Mirt. 
 
Fig. 4. Expression of c-fos mRNA after reboxetine+mirtazapine treatment as 
assessed by in situ hybridization. (a) Panels show coronal brain sections at the 
various AP coordinates from bregma (from left to right = 3.2, 1.6, -5.6, -7.8, -9.7 
mm; Paxinos and Watson, 1988) of rats treated with vehicle or 
reboxetine+mirtazapine (Reb+Mirt) (single, upper panel; repeated, lower panel). 
Scale bar is 2 mm. (b) Bar graphs showing the change of c-fos mRNA relative 
optical density (R.O.D) in vehicle- and reboxetine+mirtazapine-treated rats 
(single, upper graph; repeated, lower graph). Data are percentage of the 
respective controls (N=4 rats/group). mPFC, medial prefrontal cortex; NAc, 
nucleus accumbens; Septum, lateral septum; Hypoth, dorsomedial 
hypothalamic nucleus, dorsal part; DG, dentate gyrus; Ent, enthorrinal cortex; 
VTA SN, ventral tegmental area and substantia nigra; DR, dorsal raphe 
nucleus; LC, locus coeruleus. **p<0.01 and ***p<0.001 vs vehicle. 
 
Fig. 5. Representative coronal rat brain sections showing the expression of 
BDNF (left panels) and c-fos (right panels) mRNA at AP -2.8 mm (taken from 
bregma; Paxinos and Watson, 1988), as assessed by in situ hybridization. (a) 
Panels show the coronal brain sections of rats treated with vehicle (upper 
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panel) or reboxetine+mirtazapine (Reb+Mirt) (lower panel). Scale bar is 2 mm. 
(b) Bars represent percentage of change of the BDNF (left) and c-fos (right) 
mRNA relative optical density (R.O.D) compared to respective vehicle. N=4 
rats/group. *p<0.05 **p<0.01 and ***p<0.001 vs respective vehicle.
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Fig. S1. Microdialysis experiments showing the effect of reboxetine (Reb), 
mirtazapine (Mirt) and its combination (Reb+Mirt) on extracellular monoamines 
in rat mPFC.  Points are mean± SEM values of 4-8 rats/group. The box shows 
the fractions used to calculate AUC values in Fig. 1. *p<0.05 and **p<0.01 vs 
baseline. 
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Highlights 
 Include 3 to 5 highlights. 
 There should be a maximum of 85 characters, including spaces, per highlight. 
 Only the core results of the paper should be covered. 
 
Noradrenergic antidepressants selectively increase DA function in PFC but not in NAc 
The combination of reboxetine and mirtazapine selectively increases DA and NE in mPFC  
This evokes antidepressant-like effects (FST) and increases c-Fos and BDNF in HPC 
Citalopram pretreatment does not interfere with the effects of these drugs. 
Potentially useful in SSRI-resistant depression and negative symptom schizophrenia 
*Highlights (for review)
